Gall cleifion hefyd wedi cais i gael meddyginiaeth newydd sydd heb gael ei werthuso na’i gymeradwyo i’w ddefnyddio ar y GIG os ydyn nhw a’u meddyg yn teimlo y byddai o fudd iddynt oherwydd rhyw amgylchiadau eithriadol. Yng Nghymru, rydym wedi datblygu polisi safonol i’w ddefnyddio gan bob Bwrdd Iechyd i brosesu’r rhain fel Ceisiadau Cyllido Cleifion Unigol. Yn ddiweddar, mae’r broses hon wedi cael ei hadolygu i sicrhau bod dull cyson o benderfynu ymhob rhan o Gymru, bod modd deall y dull, a’i fod yn agored a thryloyw. Er mwyn rhoi mwy fyth o gefnogaeth i’r broses geisiadau, bydd AWMSG yn llunio rhagor o adolygiadau cyflym yn seiliedig ar dystiolaeth ar feddyginiaethau sydd eto i gael eu gwerthuso. Mae modd i’r panelau ceisiadau gael gafael ar yr un sylfaen dystiolaeth er mwyn penderfynu. Bydd hyn yn golygu llai o amrywiaeth rhwng ardaloedd yng Nghymru.
Patients may also apply for a new medicine that has not been appraised or approved for use on the NHS, if they and their doctor feel they will benefit because of some exceptional circumstances. In Wales, we have developed a standardised policy used by all Health Boards to process these as Individual Patient Funding Requests (IPFRs).  This process has recently been reviewed to ensure decision-making is consistent in all parts of Wales and is understandable, open and transparent.  To support the IPFR process even further, AWMSG will be producing more fast track evidence based reviews on new medicines that have not yet been appraised.  IPFR panels have access to the same evidence base on which to reach their decisions. All of this will mean geographical variation is minimised in Wales.